Results 321 to 330 of about 713,346 (360)
Some of the next articles are maybe not open access.
CCR1 Chemokine Receptor Antagonist
Current Pharmaceutical Design, 2003The selective accumulation and activation of leukocytes in inflamed tissues contributes to the pathogenesis of inflammatory and autoimmune diseases such as infection, rheumatoid arthritis, allergic asthma, atopic dermatitis, and multiple sclerosis. A substantial body of reports suggests that chemokines and their receptors, which belong to a family of ...
Toshihiko, Saeki, Akira, Naya
openaire +2 more sources
Receptors for calcium antagonists
The American Journal of Cardiology, 1988Calcium antagonists have been divided into 3 different subclasses represented by nifedipine, verapamil and diltiazem. These drugs have different pharmacologic effects and are not interchangeable. Previous studies suggested that all calcium antagonists bind to a 170 kd polypeptide (now called the alpha 2 subunit of the voltage-dependent calcium channel).
A, Schwartz, E, McKenna, P L, Vaghy
openaire +2 more sources
Leukotriene-receptor antagonists
The Lancet, 1999Leukotriene-receptor antagonists are the first novel class of antiasthma drugs to become available over the past three decades. They have an unique profile in that they are a hybrid of an anti-inflammatory and bronchodilator drug, and they can be taken as a tablet once or twice daily.
openaire +2 more sources
Novel P2X7 receptor antagonists
Bioorganic & Medicinal Chemistry Letters, 2003The synthesis and pharmacological evaluation of a new series of potent P2X(7) receptor antagonists is disclosed. The compounds inhibit BzATP-mediated pore formation in THP-1 cells. The distribution of the P2X(7) receptor in inflammatory cells, most notably the macrophage, mast cell and lymphocyte, suggests that P2X(7) antagonists have a significant ...
L, Alcaraz +14 more
openaire +2 more sources
Glucocorticoid Receptor Antagonists
Current Topics in Medicinal Chemistry, 2008This review covers recent progress in the discovery of selective glucocorticoid receptor (GR) antagonists. Potential therapeutic applications of selective GR antagonists are described including the pharmacological rationale and, in some cases, clinical evidence that underlies these proposed uses. Disease areas that are discussed are Cushing's syndrome,
openaire +2 more sources
lnterleukin-1 Receptor Antagonist
Critical Reviews™ in Immunology, 1995The interleukin-1 receptor antagonist (IL-1ra) is unusual in that it is the only known naturally occurring, cytokine receptor antagonist with no apparent agonist function. Over the last 5 years, since the cloning of the IL-1ra cDNA sequence, there has been intensive research on the genetics, regulation, and potential therapeutic value of this protein ...
openaire +3 more sources
Kinins, Receptors, Antagonists
1986Kinins are potent myotropic agents acting on a variety of smooth muscle preparations: isolated arteries, veins, intestines, tracheae, urinary bladders, uteri, etc. In these tissues, kinins activate at least two different receptor types, B1 and B2. B1 and B2 receptors for kinins have been identified by measuring the order of potency of agonists and the ...
openaire +2 more sources
Histamine H2-receptor antagonists
Baillière's Clinical Gastroenterology, 1988The first histamine H2-receptor antagonists were developed in the early 1970s, and they have a dominant role in today's management of peptic ulceration. The original regimens using either cimetidine or ranitidine attempted to control acidity across the 24 hours, but more 'modern' regimens use a large single dose of the H2-blocker in the evening, which ...
openaire +2 more sources